Tirzepatide

A dual GIP/GLP-1 receptor agonist approved as Mounjaro for type 2 diabetes uses and as Zepbound for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Evidence comes from large SURPASS and SURMOUNT programs, including SURMOUNT-OSA. Same incretin-class cautions as other GLP-1–pathway medicines; treat it as a labelled prescription product, not a wellness peptide.

Dual agonist at glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The dual incretin pharmacology is the leading explanation for the metabolic and weight effects seen across the labelled diabetes, weight-management, and OSA-with-obesity programs.

SURPASS (type 2 diabetes) and SURMOUNT (obesity) are large multi-trial programs. SURMOUNT-1 (PMID 35658024) is a primary obesity-program reference; SURPASS-2 (PMID 34170647) is a head-to-head diabetes trial versus semaglutide. SURMOUNT-OSA (Malhotra et al., N Engl J Med 2024; PMID 38912654; NCT05412004) was two phase 3, double-blind, randomized, placebo-controlled 52-week trials in adults with moderate-to-severe OSA and obesity: Study 5 enrolled adults unable or unwilling to use PAP (N=234 on the Zepbound label; trial 1 in the NEJM report), and Study 6 enrolled adults on PAP (N=235; trial 2). Primary endpoint was change in apnea-hypopnea index (AHI) from baseline. In the NEJM report / label-aligned figures, mean AHI change at week 52 was −25.3 events/hour with tirzepatide versus −5.3 with placebo in the non-PAP trial (estimated treatment difference −20.0; 95% CI −25.8 to −14.2; P<0.001) and −29.3 versus −5.5 in the PAP trial (difference −23.8; 95% CI −29.6 to −17.9; P<0.001). Trial arms used maximum tolerated tirzepatide 10 mg or 15 mg once weekly as a study intervention fact, not a care instruction. The FDA approved Zepbound for moderate to severe OSA in adults with obesity (December 2024 press announcement), matching the current Zepbound indication statement.

FDA-approved finished products. Mounjaro (tirzepatide) is labelled for type 2 diabetes glycemic control (adults and pediatric patients 10 years and older) and for reduction of major adverse cardiovascular events in adults with type 2 diabetes at high CV risk. Zepbound (tirzepatide) is labelled, with diet and activity, for chronic weight management in adults with obesity or overweight plus a weight-related comorbidity, and to treat moderate to severe obstructive sleep apnea in adults with obesity. The OSA indication is supported by SURMOUNT-OSA and reflected on the current Zepbound DailyMed SPL. Insurance coverage, when it exists, attaches to a labelled product and a labelled use. Compounded copies are not the labelled product.

Prescription of Mounjaro (type 2 diabetes) or Zepbound (weight management; also OSA in adults with obesity). Same compounding rule as other approved GLP-1/GIP products: a shortage workaround is not a standing generic.

Same four pathways as the Sourcing guide.

Mounjaro follows diabetes prior-auth pathways. Zepbound for obesity is commercial-plan dependent. Under the Medicare GLP-1 Bridge (1 July 2026–31 December 2027), Zepbound KwikPen is covered at $50/month for eligible Part D members; single-dose Zepbound vials and pens are not in that program. Confirm the device, not just the molecule.

Same underground as semaglutide: compounded dual-agonist vials, research-chemical listings, and counterfeit pens. Dual-agonist compounding is not equivalent to Zepbound.

Strand does not list vendors. See the grey market.

Gastrointestinal adverse events are common. Both Mounjaro and Zepbound carry a boxed warning for thyroid C-cell tumors in rodents; human relevance is unknown. Section 4 contraindications on both current labels are personal or family history of medullary thyroid carcinoma (MTC) or MEN 2, and known serious hypersensitivity to tirzepatide or product excipients. Pregnancy is labelled under section 8.1, not as a section 4 contraindication: Zepbound’s weight-reduction / OSA label advises that weight loss offers no benefit in pregnancy and may cause fetal harm, and to discontinue when pregnancy is recognized; Mounjaro’s diabetes label says use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Zepbound’s pediatric use for the labelled adult weight and OSA indications has not been established; Mounjaro has a labelled type 2 diabetes use in pediatric patients 10 years of age and older, so “minor” is not treated here as a shared section 4 contraindication across aliases. Labels also warn about gallbladder disease, pancreatitis, hypoglycemia risk when combined with insulin or insulin secretagogues, and related incretin-class cautions.

• GI effects dominate; hypoglycemia risk rises with insulin or sulfonylureas.
• Same MTC/MEN2 contraindication as GLP-1 agonists.
• Gallbladder events and a pancreatitis caution apply. Not for pregnancy.
• Device-specific coverage (KwikPen vs vial) is a real access constraint.

• SURMOUNT-OSA · 2024 · N Engl J Med

  Malhotra et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. Two phase 3 trials; primary endpoint change in AHI at 52 weeks. PMID 38912654.

• FDA Approves First Medication for Obstructive Sleep Apnea

  FDA press announcement: Zepbound approved for moderate to severe OSA in adults with obesity (20 December 2024).

• Zepbound DailyMed SPL

  Current Zepbound prescribing information: indications include OSA in adults with obesity; §4 MTC/MEN2 and hypersensitivity; §8.1 pregnancy.

• SURMOUNT-1 · 2022 · N Engl J Med

  Jastreboff et al. Tirzepatide once weekly for the treatment of obesity. PMID 35658024.

• SURPASS-2 · 2021 · N Engl J Med

  Frías et al. Tirzepatide versus semaglutide once weekly in type 2 diabetes. PMID 34170647.